BYSI BeyondSpring Inc.

16.29
+0.78  (+5%)
Previous Close 15.51
Open 15.7
Price To Book -47.91
Market Cap 377677329
Shares 23,184,612
Volume 18,796
Short Ratio
Av. Daily Volume 15,809

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint of non-inferiority vs Neulasta. NDA filing due 2020.
Plinabulin (Trial 105)
Chemotherapy-induced neutropenia (CIN)
Phase 3 second interim data due 4Q 2019.
Plinabulin (Trial 103)
Non small cell lung cancer - refractory
Phase 3 part of trial to be initiated with data due 2H 2019.
Plinabulin + TAC (Trial 106)
Chemotherapy-induced neutropenia (CIN)
Phase 1/2 initiation announced October 4, 2018.
Plinabulin + Opdivo +Yervoy
Small-cell lung cancer (SCLC)

Latest News

  1. BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
  2. BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
  3. BeyondSpring Files 2018 Annual Report on Form 20-F
  4. BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript
  5. BeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results
  6. BeyondSpring, Inc. to Host Earnings Call
  7. BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019
  8. BeyondSpring to Present at the 18th Annual Needham Healthcare Conference
  9. BeyondSpring’s Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s
  10. BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
  11. BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
  12. BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
  13. New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
  14. BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin
  15. United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036
  16. BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
  17. Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
  18. Can The Uptrend Continue for BeyondSpring (BYSI)?
  19. Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia